Clinical trials: asthma
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Asthma
A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects
This trial is a phase 1, first-in-human, randomized, double-blind, placebo-controlled dose escalation trial following single and multiple doses intravenous administration of SM17.
- Trial name
- NCT05332834
- Testing
- SM17
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Asthma
A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449
This will be a Phase I, first in human (FIH) study consisting of the following parts: Part 1a (SAD), Part 1b (IV Cohort), Part 2 (Multiple ascending dose (MAD), and Part 3 dry-powder inhalation (DPI)/ Proof of mechanism (PoM).
- Trial name
- NCT03766399
- Testing
- AZD0449
- Where
- 4 sites in Germany, New Zealand and 1 more
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Adolescent Behavior, Sleep Disturbance
Personalized Approach To Habits - Sleep
Two arm study, intervention and control, to explore the impact of an app to help high risk teens with asthma improve their sleep
- Conditions
- Adolescent Behavior, Sleep Disturbance, Asthma in Children, Knowledge, Attitudes, Practice
- Trial name
- PATH-S (NCT07029919)
- Testing
- PATH-S app
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
Asthma
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma
The primary objective of this study is to compare the pharmacokinetic (PK) profiles of Albuterol Spiromax® and ProAir HFA after administration of a single inhaled dose of 180 mcg albuterol base from each product.
- Trial name
- NCT01844401
- Testing
- Albuterol Spiromax®, ProAir® HFA
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma
This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an…
- Trial name
- NCT03371459
- Testing
- AS MDI, Proventil
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Bronchial Asthma
Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation, compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young children with persistent symptoms of asthma.
- Trial name
- NCT00497523
- Testing
- Beclomethasone dipropionate, Beclomethasone dipropionate/Salbutamol combination, Salbutamol
- Where
- 19 sites in Poland, Ukraine
- Volunteers
- 283 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Asthma
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
- Trial name
- NCT00747318
- Testing
- SKP FlutiForm HFA pMDI
- Where
- 39 sites in United States, Mexico and 3 more
- Volunteers
- 280 people
- Sponsor
- SkyePharma AG
Uncontrolled and Persistent Asthma
Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069
Study to investigate relative bioavailability of up to five different formulations of AZD5069
- Trial name
- NCT01989520
- Testing
- Phase IIb formulation, Putative phase III formulation, Slow dissolution variant 1
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
Bronchial Ablation for Treatment of Asthma (BATA) Trial
To evaluate the safety and efficacy of a bronchial radiofrequency ablation system (SyMap Medical (Suzhou) Ltd) in a population of subjects with severe asthma who are still symptomatic despite being managed on high-dose Inhaled…
- Trial name
- BATA (NCT03765307)
- Testing
- SyMap Bronchial Ablation System, Boston Scientific Alair System
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Asthma, Bronchial
Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma.
- Trial name
- NCT00092092
- Testing
- Montelukast chewable tablets, Budesonide inhaler
- Volunteers
- 71 people
- Sponsor
- Organon and Co
Asthma
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.
The purpose of this study is to assess the relative bioavailability of the AZD7594 nebulized formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04072562
- Testing
- AZD7594
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Persistent Asthma
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a…
- Trial name
- NCT02040779
- Testing
- Beclomethasone dipropionate breath-actuated inhaler, albuterol/salbutamol
- Where
- 47 sites in United States
- Volunteers
- 273 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
- Trial name
- NCT02075008
- Testing
- QGE031
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of lebrikizumab in patients with asthma whose disease remains uncontrolled despite daily therapy with an…
- Trial name
- NCT01545440
- Testing
- lebrikizumab
- Where
- 71 sites in United States, Australia
- Volunteers
- 258 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.